Healthcare Services company Vimta Labs announced 9MFY25 & Q3FY25 results Q3FY25 Financial Highlights: Total Income for Q3FY25 was at Rs 911 million. EBITDA for Q3FY25 was Rs 343 million; EBITDA margin was at 37.6%. PBT for Q3FY25 was at Rs 239 million. Q3FY25 PAT was at Rs 175 million; PAT margin was at 19.2%. Basic EPS in Q3FY25 was Rs 7.9. 9MFY25 Financial Highlights: Total Income for 9MFY25 was at Rs 2,521 million. EBITDA for 9MFY25 was Rs 915 million; EBITDA margin was at 36.3%. PBT for 9MFY25 was at Rs 640 million. 9MFY25 PAT was at Rs 484 million; PAT margin was at 19.2%. Basic EPS in 9MFY25 was Rs 21.8. Total Debt as of 31st December 2024 stood at Rs 113 million. Cash and Cash equivalents including bank balance stood at Rs 180 million as of 31st December 2024. Harita Vasireddi, Managing Director, Vimta Labs, said: "We are happy to report that Vimta Labs had another successful quarter with a strong growth of 21.1% YoY. This was mainly pushed by the Drug Development & Discovery Services. EBITDA margin for the quarter stood at 37.6% which is a growth of 496 bps on a YoY basis. During the quarter, our new addition to the Life Sciences Facility, was commercialised which has helped ease our operations giving us the space to work more efficiently. As we look to the future, we remain optimistic about our strategic direction and the robustness of our service offerings, which we believe will drive sustained growth and success.” Result PDF